Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?

International Journal of Colorectal Disease

Volumn 29, Issue 6, 2014, Pages 673-680

  Feist, Mathilde ^a   Huang, Xiaohua ^a   Müller, Joachim M ^a   Rau, Beate ^a   Dubiel, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Chemotherapy; COP9 signalosome; DNA repair; HIPEC

Indexed keywords

CASPASE 3; COP9 SIGNALOSOME; CURCUMIN; MICRORNA; MICRORNA LET 7A 1; MITOMYCIN; PROTEIN P27; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRNLET7 MICRORNA, HUMAN; MULTIPROTEIN COMPLEX; PEPTIDE HYDROLASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL DESTRUCTION; COLON CANCER; CONTROLLED STUDY; DENSITOMETRY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; IN VITRO STUDY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; PERITONEAL NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CURCUMIN; DNA DAMAGE; ENZYME ACTIVATION; HT29 CELLS; HUMANS; HYPERTHERMIA, INDUCED; MICRORNAS; MITOMYCIN; MULTIPROTEIN COMPLEXES; PEPTIDE HYDROLASES; PERITONEAL NEOPLASMS;

EID: 84901408963     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-014-1861-7     Document Type: Article

References (46)

1. Weber T, Roitman M, Link KH (2012) Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis fromcolorectal cancer. Clin Colorectal Cancer 11:167-176
2. Turaga K, Levine E, Barone R et al. (2013) Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol
3. Tsilimparis N, Bockelmann C, Raue W et al (2013) Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol 20:226-232
4. Raue W, Kilian M, Braumann C et al (2010) Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model. Int J Colorectal Dis 25:245-250
5. Spiliotis JD (2010) Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepatogastroenterology 57:1173-1177
6. Bouquet W, Boterberg T, Ceelen Wet al (2009) In vitro cytotoxicity of paclitaxel/beta-cyclodextrin complexes for HIPEC. Int J Pharm 367:148-154
7. Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237-6242
8. Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284-3292 (Pubitemid 41103684)
9. Sugarbaker PH (2007) Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 23:431-442
10. Tomasz M, Palom Y (1997) The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as themolecular basis of their activity. Pharmacol Ther 76:73-87 (Pubitemid 28078561)
11. Hannss R, Dubiel W (2011) COP9 signalosome function in the DDR. FEBS Lett 585:2845-2852
12. Deng XW, Dubiel W, Wei N et al (2000) Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. Trends Genet 16:202-203 (Pubitemid 30216544)
13. Schwechheimer C, Isono E (2010) The COP9 signalosome and its role in plant development. Eur J Cell Biol 89:157-162
14. Braus GH, Irniger S, Bayram O (2010) Fungal development and the COP9 signalosome. Curr Opin Microbiol 13:672-676
15. Kato JY, Yoneda-Kato N (2009) Mammalian COP9 signalosome. Genes Cells 14:1209-1225
16. Schmaler T, Dubiel W 2010 Control of deneddylation by the COP9 signalosome. Vol. 54. Austin, New York: Landes Bioscience and Springer Science + Business Media
17. Seeger M, Kraft R, Ferrell K et al (1998) A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. Faseb J 12:469-478 (Pubitemid 28146526)
18. Cope GA, Suh GS, Aravind L et al (2002) Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298:608-611 (Pubitemid 35215316)
19. Uhle S, Medalia O, Waldron R et al (2003) Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. Embo J 22:1302-1312 (Pubitemid 36362694)
20. Sun L, Shi L, Wang F et al (2010) Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization. J Biol Chem 286:4226-4235
21. Huang X, Wagner E, Dumdey R et al (2006) Phosphorylation by COP9 signalosome-associated CK2 promotes degradation of p27 during the G1 cell cycle phase. Israel J Chem 46:231-238 (Pubitemid 44946502)
22. Bech-Otschir D, Kraft R, Huang X et al (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. Embo J 20:1630-1639 (Pubitemid 32299400)
23. Fullbeck M, Huang X, Dumdey R et al (2005) Novel curcumin- and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cells. BMC Cancer 5:97
24. Braumann C, Tangermann J, Jacobi CA et al (2008) Novel antiangiogenic compounds for application in tumor therapy - COP9 signalosome-associated kinases as possible targets. Mini Rev Med Chem 8:421-428
25. Leppert U, Henke W, Huang X et al (2011) Post-transcriptional fine-tuning of COP9 signalosome subunit biosynthesis is regulated by the c-Myc/Lin28B/let-7 pathway. J Mol Biol 409:710-721
26. Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9-20 (Pubitemid 40064895)
27. Saha A, Deshaies RJ (2008) Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell 32:21-31
28. Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399-434
29. Schmidt MW, McQuary PR, Wee S et al (2009) F-box-directed CRL complex assembly and regulation by the CSN and CAND1. Mol Cell 35:586-597
30. Zemla A, Thomas Y, Kedziora S et al (2013) CSN- and CAND1-dependent remodelling of the budding yeast SCF complex. Nat Commun 4:1641
31. Groisman R, Polanowska J, Kuraoka I et al (2003) The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 113:357-367 (Pubitemid 36556117)
32. Dohmann EM, Levesque MP, De Veylder L et al (2008) The Arabidopsis COP9 signalosome is essential for G2 phase progression and genomic stability. Development 135:2013-2022 (Pubitemid 351943365)
33. Beli P, Lukashchuk N, Wagner SA et al (2012) Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell 46:212-225
34. Matsuoka S, Ballif BA, Smogorzewska A et al (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160-1166 (Pubitemid 46877472)
35. González-Moreno S, González-Bayón LA, Ortega-Pérez G (2010) Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2:68-75
36. Weston CR, Davis RJ (2007) The JNK signal transduction pathway. Curr Opin Cell Biol 19:142-149 (Pubitemid 46386399)
37. Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30:85-94
38. Sampson VB, Rong NH, Han J et al (2007) MicroRNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67:9762-9770 (Pubitemid 47621223)
39. Francescutti V, Rivera L, Seshadri M et al (2013) The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. Oncol Rep 30:35-42
40. Pelz JO, Vetterlein M, Grimmig T et al (2013) Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol 20:1105-1113
41. Fischer ES, Scrima A, Bohm K et al (2011) The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation. Cell 147:1024-1039
42. Echalier A, Pan Y, Birol M et al (2013) Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. Proc Natl Acad Sci U S A 110:1273-1278
43. Higa LA, Mihaylov IS, Banks DP et al (2003) Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol 5:1008-1015 (Pubitemid 37406915)
44. Sertic S, Evolvi C, Tumini E, et al. (2013) Non-canonical CRL4A/4B(CDT2) interacts with RAD18 to modulate post replication repair and cell survival. PLoS One 8:e60000
45. Hoshino I, Matsubara H (2013) MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today 43:467-478
46. Nana-Sinkam SP, Croce CM (2013) Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93:98-104